Introductory Chapter: Oral Selinexor, a Selective Inhibitor of Nuclear Export in the Treatment of Patients with Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents and Monoclonal Antibodies
Reference30 articles.
1. Turner JG, Sullivan DM. CRM1 mediated nuclear export of proteins and drug resistance in cancer. Current Medicinal Chemistry. 2008; 15(26): 2648-2655. DOI: 10.2174/092986708786242859
2. Nguen KT, Holloway MP, Altura RA. The CRM1 nuclear export protein in normal development and disease. International Journal of Biochemistry and Molecular Biology. 2012; 3(2): 137-151. PMID: 22773955/ISSN: 2152-4114/ IJBM 1204001
3. Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Seminars in Cance Biology. 2014; 27: 62-73. DOI: 10.1016/j.semcancer.2014.03.001
4. Gravina GL, Senapedis W, Mc Cauley D, Baloglu E, Shacham S, Festuccia C. Nucleo-cytoplasmic transport as a therapeutic target of cancer. Journal of Hematology & Oncology. 2014; 7: 85. DOI: 10.1186/s13045-014-0085-1
5. Lu C, Figueroa JA, Liu Z, Konala V, Aulakh A, Verma R, et al. Nuclear export as a novel therapeutic target: the CRM1 connection. Current Cancer Drug Targets. 2015; 15(7): 575-592. DOI: 10.2174/156800961507150828223554